Therapy Watch launches new tracker covering pulmonary arterial hypertension (PAH)

Therapy Watch Pulmonary Arterial Hypertension (PAH) is launching in the US market, with expansion into other geographies including Europe in early 2024.

PAH, a chronic and progressive condition, is caused by elevated blood pressure in the pulmonary artery. This rare condition affects an estimated 15-50 individuals per million in the US.

Patient record form (PRF) insights will be collected via online interviews with a panel of Pulmonologists and Cardiologists who are specialized in the treatment of PAH.

The new study will delve into a range of topics including the drivers behind treatment decisions, the real-world usage of mono/dual/triple therapy combinations, the treatment pathway and timings, how the physician setting affects treatments prescribed, and impact of new launches on the market dynamics.

Therapy Watch is a syndicated market tracking tool that provides market researchers and marketing teams and with real-world evidence into prescribing behaviors and market dynamics. Contact us today to learn more about our new PAH study and how it could help address your business questions.